EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models

Razia Aslam, Cathy E Richards, Joanna Fay iD, Lance Hudson, Julie Workman iD, Cha Len Lee, Adrian Murphy, Brian O'Neill, Sinead Toomey, Bryan T Hennessy

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252413264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Razia Aslam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Group, Department of Medicine, RCSI University of Medicine and Health Sciences, D09 YD60 Dublin, Ireland. Hauptthemen laut MEDLINE: Purines, Aminopyridines, Colorectal Neoplasms, Drug Synergism. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North East Cancer Research and Education Trust, St Luke's Institute of Cancer Research, RCSI StAR MD Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CDK4/6 inhibitor Ribociclib has shown limited efficacy as a monotherapy in colorectal cancer (CRC). However, combining Ribociclib with targeted therapies could present a viable strategy for treating CRC. This study evaluated the combination of Ribociclib and the PI3K inhibitor Alpelisib across four distinct cell lines representing different mutational statuses (PIK3CA/KRAS wild-type, KRAS-mutated, PIK3CA-mutated, and PIK3CA/KRAS-mutated). We analyzed the drugs’ impact on key proteins involved in the PI3K pathway, cell cycle regulation, and apoptosis. The combination of Alpelisib and Ribociclib demonstrated a synergistic anti-proliferative effect across all cell lines, leading to a simultaneous decrease in pRB, pAKT, and p-S6 levels, and a more comprehensive suppression of the PI3K/AKT/mTOR pathway. Additionally, there was an upregulation of the apoptotic marker, p-BCL2, in cells treated with the combination compared to controls. In vivo studies using Caco-2, LS1034, and SNUC4 xenografts revealed a significant reduction in tumour growth with the combination therapy compared to single-agent treatments. These findings suggest that combining Alpelisib and Ribociclib could be a promising therapeutic approach for CRC, warranting further clinical exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PurinesAminopyridinesColorectal NeoplasmsDrug SynergismCyclin-Dependent Kinase 6ThiazolesCyclin-Dependent Kinase 4Xenograft Model Antitumor AssaysApoptosisCell ProliferationHumansAnimalsMiceCell Line, TumorPhosphoinositide-3 Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCaco-2 CellsMice, NudeSignal TransductionFemale

Stichwörter der Autor:innen

alpelisibcolorectal cancerdrug combinationsribociclibtargeted therapies

Substanzen

ribociclibPurinesAminopyridinesAlpelisibCyclin-Dependent Kinase 6ThiazolesCyclin-Dependent Kinase 4Phosphoinositide-3 Kinase InhibitorsCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Medical Oncology Group, Department of Medicine, RCSI University of Medicine and Health Sciences, D09 YD60 Dublin, Ireland.
  • Beaumont RCSI Cancer Centre, D09 YD60 Dublin, Ireland.
  • Department of Medical Oncology, St James's Hospital, D08 NHY1 Dublin, Ireland.
  • RCSI Biobank, RCSI University of Medicine and Health Sciences, D09 YD60 Dublin, Ireland.
  • Department of Pathology, RCSI University of Medicine and Health Science, D09 YD60 Dublin, Ireland.
  • Department of Surgery, RCSI University of Medicine and Health Science, D09 YD60 Dublin, Ireland.

ORCID-Profile: Joanna Fay, Julie Workman

Förderung

  • North East Cancer Research and Education Trust
  • St Luke's Institute of Cancer Research
  • RCSI StAR MD Programme
  • Luke’s Institute of Cancer Research (SLICR)
  • RCSI/Hermitage Clinic StAR MD Programme

Zitieren

APA

Aslam, R., Richards, C. E., Fay, J., Hudson, L., Workman, J., Lee, C. L., Murphy, A., O'Neill, B., Toomey, S., & Hennessy, B. T. (2024). Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413264

Vancouver

Aslam R, Richards CE, Fay J, Hudson L, Workman J, Lee CL, et al. Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413264

BibTeX
@article{Aslam2024,
  author = {Aslam, Razia and Richards, Cathy E and Fay, Joanna and Hudson, Lance and Workman, Julie and Lee, Cha Len and Murphy, Adrian and O'Neill, Brian and Toomey, Sinead and Hennessy, Bryan T},
  title = {Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252413264}
}
Kostenlos starten →